Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Women who received a combination of Kisqali and hormone therapy lived twice as long without their cancer getting worse.
Adding an AKT inhibitor to fulvestrant doubled progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Assay can also help identify patients who may benefit from ovarian suppression therapy.
Differences in the tumor environment may help explain why Black women are more prone to aggressive breast cancer.
Patients whose treatment was guided by measurement of tumor cells in the blood had improved survival outcomes.
Most women who interrupted endocrine therapy were able to conceive, and more than 60% gave birth.
Research also showed that treatment before surgery benefits patients with HER2-low breast cancer.
Genomic testing is an important tool to guide treatment decisions among women with early-stage breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.